Current Size: 100%
Survival statistics
Cancer | Years | Method | Sex | Age | Survived | Net survival | 95% lower | 95% upper |
---|---|---|---|---|---|---|---|---|
All ex C44 | 1994-1998 | cohort | Both | 15-99 | 1.00 years | 62.2% | 61.8% | 62.6% |
All ex C44 | 1994-1998 | cohort | Both | 15-99 | 5.00 years | 44.4% | 43.9% | 44.9% |
All ex C44 | 1994-1998 | cohort | Both | 15-99 | 10.00 years | 41.5% | 40.8% | 42.3% |
All ex C44 | 1999-2003 | cohort | Both | 15-99 | 1.00 years | 67.3% | 66.9% | 67.6% |
All ex C44 | 1999-2003 | cohort | Both | 15-99 | 5.00 years | 51.1% | 50.6% | 51.5% |
All ex C44 | 1999-2003 | cohort | Both | 15-99 | 10.00 years | 47.4% | 46.7% | 48.1% |
All ex C44 | 2004-2008 | cohort | Both | 15-99 | 1.00 years | 72.8% | 72.4% | 73.1% |
All ex C44 | 2004-2008 | cohort | Both | 15-99 | 5.00 years | 57.8% | 57.4% | 58.2% |
All ex C44 | 2004-2008 | cohort | Both | 15-99 | 10.00 years | 54.4% | 53.6% | 55.2% |
All ex C44 | 2009-2013 | cohort | Both | 15-99 | 1.00 years | 77.4% | 77.1% | 77.7% |
All ex C44 | 2009-2013 | cohort | Both | 15-99 | 5.00 years | 62.4% | 61.9% | 62.9% |
All ex C44 | 2010-2014 | hybrid | Both | 15-99 | 1.00 years | 77.4% | 77.1% | 77.7% |
All ex C44 | 2010-2014 | hybrid | Both | 15-99 | 5.00 years | 62.4% | 62.0% | 62.8% |
All ex C44 | 2010-2014 | hybrid | Both | 15-99 | 10.00 years | 58.5% | 57.9% | 59.2% |